Centessa PharmaceuticalsCNTA
Market Cap: $1.62B
About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Employees: 75
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
341% more call options, than puts
Call options by funds: $119K | Put options by funds: $27K
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
16% more funds holding
Funds holding: 69 [Q1] → 80 (+11) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
1.46% less ownership
Funds ownership: 78.39% [Q1] → 76.93% (-1.46%) [Q2]
9% less capital invested
Capital invested by funds: $865M [Q1] → $785M (-$79.5M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Oppenheimer Francois Brisebois 60% 1-year accuracy 18 / 30 met price target | 2%downside $14 | Outperform Reiterated | 14 Aug 2024 |
Oppenheimer Francois Brisebois 60% 1-year accuracy 18 / 30 met price target | 2%downside $14 | Outperform Initiated | 18 Jul 2024 |
Morgan Stanley Matthew Harrison 54% 1-year accuracy 13 / 24 met price target | 23%downside $11 | Equal-Weight Maintained | 21 Jun 2024 |
Financial journalist opinion
Based on 3 articles about CNTA published over the past 30 days